CDKN2A and squamous cell lung carcinoma: It has been demonstrated that promoter methylation in sputum increases with cancer risk [29], increases as the time to lung cancer decreases [147], and in the case of CDKN2A/p16 and/or MGMT, can be found in sputum up to 3 years before diagnosis of squamous cell lung cancer [149].